SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
1. Rocket Pharmaceuticals faces securities litigation over misleading information on clinical trials. 2. FDA placed a clinical hold on RP-A501 study due to serious adverse events. 3. Rocket's stock price fell 37% following the announcement of the FDA hold. 4. Investors are encouraged to discuss legal options with Faruqi & Faruqi. 5. August 11, 2025, is the deadline for potential class action lead plaintiff.